

Sofia I Agelaki

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6152081/sofia-i-agelaki-publications-by-year.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

101 papers	3,510 citations	31 h-index	58 g-index
110 ext. papers	4,013 ext. citations	4.6 avg, IF	4.78 L-index

#	Paper	IF	Citations
101	Correlation of Clinical Parameters with Intracranial Outcome in Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Pd-1/Pd-L1 Inhibitors as Monotherapy. <i>Cancers</i> , 2021 , 13,	6.6	4
100	Mir-34a as predictor of immunotherapy efficacy in NSCLC patients.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e21191-e21191	2.2	0
99	Predictive and prognostic significance of PIOS (Patras Immunotherapy Score) model in patients with advanced NSCLC treated with nivolumab or pembrolizumab: Results from a validation cohort.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e21164-e21164	2.2	
98	MicroRNAs Regulating Tumor Immune Response in the Prediction of the Outcome in Patients With Breast Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021 , 8, 668534	5.6	4
97	Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study. <i>PLoS ONE</i> , 2021 , 16, e0252537	3.7	3
96	A Prognostic Role for Circulating microRNAs Involved in Macrophage Polarization in Advanced Non-Small Cell Lung Cancer. <i>Cells</i> , 2021 , 10,	7.9	3
95	Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study. <i>Translational Lung Cancer Research</i> , 2021 , 10, 3538-3549	4.4	4
94	Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer. <i>ESMO Open</i> , 2021 , 6, 100254	6	6
93	Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
92	Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a Real-Life Setting. <i>Cancers</i> , 2020 , 12,	6.6	2
91	Epithelial/Mesenchymal Characteristics and PD-L1 Co-Expression in CTCs of Metastatic Breast Cancer Patients Treated with Eribulin: Correlation with Clinical Outcome. <i>Cancers</i> , 2020 , 12,	6.6	3
90	Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy. <i>Cancers</i> , 2020 , 12,	6.6	11
89	Clinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer. <i>Cancers</i> , 2020 , 12,	6.6	23
88	Molecular markers related to immunosurveillance as predictive and monitoring tools in non-small cell lung cancer: recent accomplishments and future promises. <i>Expert Review of Molecular Diagnostics</i> , 2020 , 20, 335-344	3.8	6
87	BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects. <i>International Journal of Cancer</i> , 2020 , 147, 1334-1342	7.5	3
86	MicroRNAs involved in immune response as prognostic markers in early and metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e15528-e15528	2.2	2
85	Circulating MicroRNAs Regulating DNA Damage Response and Responsiveness to Cisplatin in the Prognosis of Patients with Non-Small Cell Lung Cancer Treated with First-Line Platinum Chemotherapy. <i>Cancers</i> , 2020 , 12,	6.6	10

84	Intergration of common clinical and laboratory parameters for predictive modeling of outcome with immune checkpoint inhibitors (ICIs) in patients (pts) with Nnon-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e21609-e21609	2.2	0
83	Third Harmonic Generation microscopy distinguishes malignant cell grade in human breast tissue biopsies. <i>Scientific Reports</i> , 2020 , 10, 11055	4.9	10
82	Detection of G12/G13 Mutations in Cell Free-DNA by Droplet Digital PCR, Offers Prognostic Information for Patients with Advanced Non-Small Cell Lung Cancer. <i>Cells</i> , 2020 , 9,	7.9	7
81	Nonlinear imaging of female breast tissue biopsies 2019 ,		1
80	Cancer cachexia, sarcopenia and hand-GRIP strength (HGS) in the prediction of outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs): A prospective, observational study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9099-9099	2.2	1
79	Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancer. <i>Oncotarget</i> , 2019 , 10, 966-981	3.3	31
78	Taxane & cyclophosphamide vs anthracycline & taxane-based chemotherapy as adjuvant treatment for breast cancer: a pooled analysis of randomized controlled trials by the Hellenic Academy of Oncology. <i>Oncotarget</i> , 2019 , 10, 1209-1216	3.3	8
77	Role of the expression of PD-L1 and CD47 on circulating tumor cells (CTCs) in the prediction of outcome in metastatic breast cancer (mBC) patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e14045-e14045	2.2	1
76	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 134, 39-45	7	129
75	Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 437-447	6.1	84
74	Detection of the T cell activation state using nonlinear optical microscopy. <i>Journal of Biophotonics</i> , 2019 , 12, e201800277	3.1	9
73	Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer. <i>Breast Cancer Research</i> , 2018 , 20, 72	8.3	39
72	Role of circulating miRNAs in detecting metastasis and having prognostic significance in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1086-1086	2.2	1
71	Expression of insulin-like growth factor-1 receptor in circulating tumor cells of patients with breast cancer is associated with patient outcomes. <i>Molecular Oncology</i> , 2018 , 12, 21-32	7.9	8
70	Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group. <i>British Journal of Cancer</i> , 2017 , 117, 8-14	8.7	22
69	Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients. <i>Oncotarget</i> , 2017 , 8, 5309-5322	3.3	24
68	A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer. <i>Cellular Physiology and Biochemistry</i> , 2017 , 44, 594-606	3.9	31
67	Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group. <i>British Journal of Cancer</i> , 2017 , 117, 164-170	8.7	7

66	Distinction between breast cancer cell subtypes using third harmonic generation microscopy. <i>Journal of Biophotonics</i> , 2017 , 10, 1152-1162	3.1	15
65	Prognostic value of circulating tumor cells in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20520-e20520	2.2	
64	Circulating microRNAs (miRNAs) as predictors of relapse in early breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, e23030-e23030	2.2	
63	Association of Ki-67 expression in CTCs with disease relapse in patients with early breast cancer (BC) and affect by the administration of adjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e23243-e23243	2.2	
62	Circulating Biomarkers in Non-Small-Cell Lung Cancer: Current Status and Future Challenges. <i>Clinical Lung Cancer</i> , 2016 , 17, 507-516	4.9	36
61	The promise of immunotherapy in head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2016 , 27, 1675-85	10.3	61
60	A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 77, 949-56	3.5	11
59	Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 821-7	3.5	18
58	Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients. <i>Breast Cancer Research</i> , 2015 , 17, 113	8.3	21
57	Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer. <i>BMC Cancer</i> , 2015 , 15, 399	4.8	93
56	ERCC1 SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy. <i>Cancer Investigation</i> , 2015 , 33, 107-13	2.1	12
55	Detection of circulating tumor cells in the peripheral blood of patients with small cell lung cancer (SCLC) using both the CellSearch platform and immunofluorescence: Correlation with clinicopathological features.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 7573-7573	2.2	1
54	Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer. <i>PLoS ONE</i> , 2015 , 10, e0123683	3.7	38
53	Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. <i>Lancet Oncology, The</i> , 2014 , 15, 406-14	21.7	566
52	Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 73, 685-93	3.5	27
51	Detection of circulating cytokeratin-19 mRNA-positive cells in the blood and the mitotic index of the primary tumor have independent prognostic value in early breast cancer. <i>Clinical Breast Cancer</i> , 2014 , 14, 442-50	3	7
50	Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy. <i>Breast Cancer Research</i> , 2014 , 16, 485	8.3	42
49	Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer. <i>BMC Cancer</i> , 2014 , 14, 651	4.8	75

48	Effect of exemestane plus everolimus on CTC counts and Ki-67 expression on CTCs in patients with advanced hormone receptor-positive, HER2-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 11042-11042	2.2	
47	Familial mesothelioma in first degree relatives. <i>Diagnostic Cytopathology</i> , 2013 , 41, 654-7	1.4	2
46	Predictive and prognostic value of LPS-stimulated cytokine secretion in metastatic non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2013 , 15, 903-9	3.6	7
45	Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 71, 605-12	3.5	11
44	Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. <i>Cancer</i> , 2013 , 119, 2754-64	6.4	9 ¹
43	A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group. <i>Journal of Chemotherapy</i> , 2013 , 25, 49-55	2.3	39
42	Apoptotic circulating tumor cells in early and metastatic breast cancer patients. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 1886-95	6.1	77
41	Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer. <i>British Journal of Cancer</i> , 2013 , 108, 549-56	8.7	29
40	Evaluation of proliferation and apoptosis markers in circulating tumor cells (CTCs) of women with early breast cancer who are candidates for tumor dormancy.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e22101-e22101	2.2	10 ²
39	A pilot feasibility study to evaluate the efficacy of lapatinib in eliminating HER2-positive tumor cells circulating in peripheral blood of women with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e22105-e22105	2.2	
38	A multicenter phase I-II trial of weekly paclitaxel and carboplatin plus bevacizumab in women with triple-negative metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1045-1045	2.2	
37	A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2012 , 13, 129-35	4.9	7
36	Elderly and younger patients with non-small cell lung cancer (NSCLC) derive similar benefit from second-line chemotherapy: A retrospective subset analysis of second-line chemotherapy trials conducted from the Hellenic Cooperative Research Group (HORG).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7564-7564	2.2	
35	Targeting the insulin-like growth factor I receptor inhibits proliferation and VEGF production of non-small cell lung cancer cells and enhances paclitaxel-mediated anti-tumor effect. <i>Lung Cancer</i> , 2011 , 73, 158-65	5.9	17
34	Non-platinum-based first-line followed by platinum-based second-line chemotherapy or the reverse sequence in patients with advanced non-small cell lung cancer: a retrospective analysis by the lung cancer group of the Hellenic Oncology Research Group. <i>Oncology</i> , 2010 , 78, 229-36	3.6	3
33	Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. <i>Cancer Letters</i> , 2010 , 288, 99-106	9.9	23 ⁰
32	Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer. <i>British Journal of Cancer</i> , 2009 , 101, 589-97	8.7	87
31	Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2177-84	2.2	225

30	Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance. <i>Breast Cancer Research and Treatment</i> , 2009 , 117, 525-34	4.4	41
29	A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 64, 785-91	3.5	1
28	A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer. <i>Lung Cancer</i> , 2009 , 65, 187-91	5.9	30
27	Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. <i>Breast Cancer Research</i> , 2009 , 11, R84	8.3	93
26	Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. <i>Breast Cancer Research</i> , 2008 , 10, R80	8.3	103
25	A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2007 , 97, 43-9	8.7	5
24	Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. <i>BMC Cancer</i> , 2007 , 7, 91	4.8	81
23	Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial. <i>Digestive Diseases</i> , 2007 , 25, 100-5	3.2	2
22	Activation of FAK/PI3K/Rac1 signaling controls actin reorganization and inhibits cell motility in human cancer cells. <i>Cellular Physiology and Biochemistry</i> , 2007 , 20, 977-86	3.9	78
21	A retrospective analysis of second-line chemotherapy or best supportive care in patients with advanced-stage non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2006 , 8, 49-55	4.9	8
20	Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors. <i>Clinical Cancer Research</i> , 2005 , 11, 4151-9	12.9	13
19	Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. <i>Expert Opinion on Emerging Drugs</i> , 2005 , 10, 855-74	3.7	8
18	A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer. <i>Oncology</i> , 2004 , 66, 192-6	3.6	11
17	A multicenter phase II study of the combination of gemcitabine and docetaxel in previously treated patients with small cell lung cancer. <i>Lung Cancer</i> , 2004 , 43, 329-33	5.9	15
16	Fatal Nocardia farcinica bacteremia in a patient with lung cancer. <i>Diagnostic Microbiology and Infectious Disease</i> , 2004 , 50, 135-9	2.9	15
15	Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer. <i>Annals of Oncology</i> , 2003 , 14, 388-94	10.3	34
14	A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors. <i>Annals of Oncology</i> , 2003 , 14, 304-12	10.3	29
13	Nonneutropenic febrile episodes associated with docetaxel-based chemotherapy in patients with solid tumors. <i>Cancer</i> , 2002 , 95, 1326-33	6.4	10

12	Corticotropin-releasing hormone augments proinflammatory cytokine production from macrophages in vitro and in lipopolysaccharide-induced endotoxin shock in mice. <i>Infection and Immunity</i> , 2002 , 70, 6068-74	3.7	127
11	Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2651-7	2.2	112
10	Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes. <i>British Journal of Cancer</i> , 2001 , 85, 798-802	8.7	7
9	A dose-finding study of the weekly administration of paclitaxel in patients with advanced solid tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2001 , 24, 404-7	2.7	10
8	Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study. <i>Annals of Oncology</i> , 2001 , 12, 193-7	10.3	37
7	Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter phase II study. <i>Annals of Oncology</i> , 2000 , 11, 1249-54	10.3	25
6	A dose escalation study of weekly docetaxel in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2000 , 46, 488-92	3.5	21
5	Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2000 , 23, 341-4	2.7	92
4	Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group. <i>Annals of Oncology</i> , 1999 , 10, 211-5	10.3	73
3	Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. The Greek Breast Cancer Cooperative Group (GBCCG). <i>Annals of Oncology</i> , 1999 , 10, 547-52	10.3	31
2	First-line treatment with mitoxantrone, methotrexate, vincristine, and carboplatine (MIMOC) plus cyclical hormonotherapy with tamoxifen and megestrol acetate in advanced breast cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1999 , 22, 273-7	2.7	5
1	Treatment of non-small-cell lung cancer with prolonged oral etoposide. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1998 , 21, 505-8	2.7	42